Vident Investment Advisory’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-40,822
| Closed | -$19.1M | – | 572 |
|
|
2023
Q2 | $19.1M | Sell |
40,822
-1,089
| -3% | -$457K | 0.66% | 17 |
|
|
2023
Q1 | $14.4M | Buy |
41,911
+13,798
| +49% | +$4.65M | 0.47% | 42 |
|
|
2022
Q4 | $10.3M | Buy |
28,113
+21,326
| +314% | +$7.56M | 0.39% | 47 |
|
|
2022
Q3 | $899K | Buy |
6,787
+1,799
| +36% | +$570K | 0.03% | 621 |
|
|
2022
Q2 | $1.62M | Sell |
4,988
-4,074
| -45% | -$1.22M | 0.05% | 467 |
|
|
2022
Q1 | $2.59M | Sell |
9,062
-10,604
| -54% | -$2.73M | 0.07% | 342 |
|
|
2021
Q4 | $5.43M | Buy |
19,666
+7,371
| +60% | +$1.87M | 0.14% | 165 |
|
|
2021
Q3 | $2.84M | Sell |
12,295
-6,664
| -35% | -$1.64M | 0.09% | 254 |
|
|
2021
Q2 | $4.35M | Buy |
18,959
+4,794
| +34% | +$963K | 0.13% | 150 |
|
|
2021
Q1 | $2.65M | Buy |
14,165
+3,943
| +39% | +$771K | 0.09% | 250 |
|
|
2020
Q4 | $1.73M | Sell |
10,222
-829
| -8% | -$124K | 0.07% | 339 |
|
|
2020
Q3 | $1.64M | Buy |
11,051
+1,407
| +15% | +$218K | 0.08% | 310 |
|
|
2020
Q2 | $1.58M | Sell |
9,644
-699
| -7% | -$107K | 0.08% | 285 |
|
|
2020
Q1 | $1.44M | Buy |
10,343
+3,078
| +42% | +$423K | 0.09% | 276 |
|
|
2019
Q4 | $955K | Sell |
7,265
-698
| -9% | -$80.9K | 0.06% | 410 |
|
|
2019
Q3 | $891K | Buy |
7,963
+229
| +3% | +$25.5K | 0.08% | 192 |
|
|
2019
Q2 | $857K | Buy |
7,734
+686
| +10% | +$80.8K | 0.07% | 193 |
|
|
2019
Q1 | $914K | Sell |
7,048
-1,860
| -21% | -$226K | 0.05% | 430 |
|
|
2018
Q4 | $1.03M | Buy |
8,908
+679
| +8% | +$75.8K | 0.06% | 418 |
|
|
2018
Q3 | $883K | Sell |
8,229
-2,511
| -23% | -$251K | 0.03% | 504 |
|
|
2018
Q2 | $917K | Sell |
10,740
-1,256
| -10% | -$103K | 0.04% | 450 |
|
|
2018
Q1 | $961K | Buy |
11,996
+241
| +2% | +$19.4K | 0.04% | 403 |
|
|
2017
Q4 | $992K | Sell |
11,755
-2,957
| -20% | -$252K | 0.04% | 378 |
|
|
2017
Q3 | $1.26M | Buy |
14,712
+10,989
| +295% | +$901K | 0.07% | 336 |
|
|
2017
Q2 | $306K | Sell |
3,723
-66
| -2% | -$5.38K | 0.03% | 379 |
|
|
2017
Q1 | $319K | Sell |
3,789
-6,774
| -64% | -$543K | 0.03% | 366 |
|
|
2016
Q4 | $777K | Buy |
10,563
+4,323
| +69% | +$322K | 0.09% | 297 |
|
|
2016
Q3 | $501K | Sell |
6,240
-2,464
| -28% | -$197K | 0.07% | 345 |
|
|
2016
Q2 | $685K | Sell |
8,704
-19,656
| -69% | -$1.48M | 0.1% | 324 |
|
|
2016
Q1 | $2.04K | Buy |
28,360
+11,702
| +70% | +$885K | 0.13% | 300 |
|
|
2015
Q4 | $1.4M | Sell |
16,658
-8,287
| -33% | -$688K | 0.18% | 262 |
|
|
2015
Q3 | $2.09M | Buy |
24,945
+11,366
| +84% | +$960K | 0.29% | 70 |
|
|
2015
Q2 | $1.13M | Buy |
13,579
+1,014
| +8% | +$77.3K | 0.15% | 186 |
|
|
2015
Q1 | $913K | Sell |
12,565
-4,022
| -24% | -$286K | 0.18% | 149 |
|
|
2014
Q4 | $1.14M | Buy |
+16,587
| New | +$1.12M | 0.39% | 28 |
|
Other funds holding LLY
Vident Investment Advisory's LLY Position: Q3 2023 in Review
Vident Investment Advisory sold out of Eli Lilly (LLY) in Q3 2023, closing a stake of 40,822 shares — an estimated $19.1M sold.
Vident Investment Advisory first reported a position in LLY in Q4 2014 and held it in 35 quarters. The position peaked at $19.1M in Q2 2023. 2,974 funds tracked by Wall St. Rank hold LLY as of Q3 2023.
- Vident Investment Advisory reported no remaining Eli Lilly position as of Q3 2023 after selling out during the quarter.
- Vident Investment Advisory sold 40,822 Eli Lilly shares in Q3 2023, an estimated $19.1M.
- Vident Investment Advisory first reported a position in Eli Lilly in Q4 2014 and held it in 35 quarters.
- Vident Investment Advisory's Eli Lilly position peaked at $19.1M in Q2 2023.
- 2,974 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2023.
Based on Vident Investment Advisory's 13F filing for Q3 2023.